Research view
Switch to patient viewColorectal cancer: trials that stopped early
Trials on Colorectal cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
254 stopped trials give a reason in the registry, latest registry update first. 4 more give no reason and are not listed.
Terminated
Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers
Reason given in the registry “Due to a lack of safety and efficacy.”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Jan 2025.
- Ended
- Jul 2024
- Phase
- Phase 1
- Run by
- The Netherlands Cancer Institute
- Registry record
- NCT04916236
Terminated
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
Reason given in the registry “Study was terminated due to strategic considerations and not due to safety.”
Quoted unchanged from ClinicalTrials.gov; record updated 16 Jan 2025.
- Ended
- Nov 2023
- Phase
- Phase 1
- Run by
- Pfizer
- Registry record
- NCT04171141
Terminated
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Reason given in the registry “Required re-formulation of DFMO from IV to capsule to maintain safety”
Quoted unchanged from ClinicalTrials.gov; record updated 24 Dec 2024.
- Ended
- Dec 2024
- Phase
- Phase 1/2
- Run by
- Aminex Therapeutics, Inc.
- Registry record
- NCT05500508
Terminated
Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)
Reason given in the registry “The overall profile does not support development for metastatic colorectal cancer”
Quoted unchanged from ClinicalTrials.gov; record updated 20 Dec 2024.
- Ended
- Mar 2024
- Phase
- Phase 1
- Run by
- Taipei Medical University Shuang Ho Hospital
- Registry record
- NCT05281276
Withdrawn
Improving Outpatient Colonoscopy Bowel Prep With the Orton Score
Reason given in the registry “Not enough funding for research coordinator.”
Quoted unchanged from ClinicalTrials.gov; record updated 12 Dec 2024.
- Ended
- Dec 2024
- Run by
- University of Virginia
- Registry record
- NCT04093557
Withdrawn
Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
Reason given in the registry “PI left the institution”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Dec 2024.
- Ended
- Dec 2024
- Phase
- Phase 1
- Run by
- University of Colorado, Denver
- Registry record
- NCT03802747
Terminated
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
Reason given in the registry “Due to development strategy change.”
Quoted unchanged from ClinicalTrials.gov; record updated 6 Dec 2024.
- Ended
- Jun 2024
- Phase
- Phase 1
- Run by
- ABM Therapeutics Corporation
- Registry record
- NCT05831995
Terminated
Comparison Between Tailored Surgery Versus Total Mesorectal Excision in ycT2-3N0M0
Reason given in the registry “the high proportion of patients requiring TME(control group) suggests that proceeding with a randomized prospective clinical trial may not be feasible.”
Quoted unchanged from ClinicalTrials.gov; record updated 5 Dec 2024.
- Ended
- Aug 2024
- Run by
- Seoul National University Hospital
- Registry record
- NCT05164315
Withdrawn
Effectiveness of Aquatic Exercise on Fatigue, Neuropathy and Quality of Life Among Cancer Patients
Reason given in the registry “The study was stopped because we were unable to recruit participants as planned. Therefore, it was decided to halt the study and participant recruitment.”
Quoted unchanged from ClinicalTrials.gov; record updated 26 Nov 2024.
- Ended
- Nov 2024
- Run by
- Tel Aviv University
- Registry record
- NCT05427344
Terminated
ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer
Reason given in the registry “Company decision to wind down operations, close all clinical programs and evaluate strategic options”
Quoted unchanged from ClinicalTrials.gov; record updated 21 Nov 2024.
- Ended
- Jul 2024
- Phase
- Phase 1
- Run by
- MEI Pharma, Inc.
- Registry record
- NCT05824559
Withdrawn
Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer
Reason given in the registry “Abandoned 9/23/24”
Quoted unchanged from ClinicalTrials.gov; record updated 21 Nov 2024.
- Phase
- Phase 2
- Run by
- City of Hope Medical Center
- Registry record
- NCT06575725
Withdrawn
Chromoendoscopy or Narrow Band Imaging (NBI) for Improving Adenoma Detection in Colonoscopy
Reason given in the registry “PI decision.”
Quoted unchanged from ClinicalTrials.gov; record updated 6 Nov 2024.
- Ended
- Feb 2025
- Run by
- Indiana University
- Registry record
- NCT04192929
Terminated
A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination
Reason given in the registry “Strategic business decision”
Quoted unchanged from ClinicalTrials.gov; record updated 6 Nov 2024.
- Ended
- Aug 2024
- Phase
- Phase 1
- Run by
- Pfizer
- Registry record
- NCT06448364
Terminated
Exercise Preconditioning with Cancer Surgeries
Reason given in the registry “Company providing the computer application for exercise intervention suddenly closed for business”
Quoted unchanged from ClinicalTrials.gov; record updated 16 Oct 2024.
- Ended
- Sept 2024
- Run by
- University of Virginia
- Registry record
- NCT04923672
Terminated
Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC
Reason given in the registry “Due to poor clinical trial accrual, the study was terminated.”
Quoted unchanged from ClinicalTrials.gov; record updated 15 Oct 2024.
- Ended
- Dec 2023
- Phase
- Phase 2
- Run by
- Shanghai Henlius Biotech
- Registry record
- NCT05584137
Terminated
PS101-mediated ACT With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin
Reason given in the registry “Business reason”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Oct 2024.
- Ended
- Sept 2024
- Phase
- Phase 1
- Run by
- EXACT Therapeutics AS
- Registry record
- NCT04021277
Withdrawn
Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)
Reason given in the registry “prioritization of studies”
Quoted unchanged from ClinicalTrials.gov; record updated 26 Sept 2024.
- Ended
- Oct 2026
- Phase
- Phase 2
- Run by
- Roswell Park Cancer Institute
- Registry record
- NCT05518032
Withdrawn
Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer
Reason given in the registry “Lack of funding.”
Quoted unchanged from ClinicalTrials.gov; record updated 20 Sept 2024.
- Ended
- Jun 2026
- Phase
- Phase 3
- Run by
- Johannes Laengle, MD, PhD
- Registry record
- NCT04488159
Terminated
Well-being and Stress Control After Colorectal Surgery
Reason given in the registry “recruitment difficulties”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Sept 2024.
- Ended
- Sept 2024
- Run by
- University Hospital, Strasbourg, France
- Registry record
- NCT03844347
Withdrawn
Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study
Reason given in the registry “no sites were regulatory ready and the SC took the study to a different group.”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Sept 2024.
- Ended
- Sept 2024
- Phase
- Phase 2
- Run by
- Academic and Community Cancer Research United
- Registry record
- NCT05356897
Withdrawn
Intraperitoneal LSTA1 in CRS-HIPEC
Reason given in the registry “closed early due to low (0) accrual”
Quoted unchanged from ClinicalTrials.gov; record updated 20 Aug 2024.
- Ended
- Jun 2024
- Phase
- Phase 1
- Run by
- University of California, San Diego
- Registry record
- NCT06216561
Terminated
Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients
Reason given in the registry “Business Decision”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Aug 2024.
- Ended
- Jun 2024
- Phase
- Phase 1
- Run by
- Asahi Kasei Therapeutics, Inc.
- Registry record
- NCT05251727
Withdrawn
Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
Reason given in the registry “withdrawn”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Aug 2024.
- Ended
- Oct 2025
- Phase
- Early phase 1
- Run by
- City of Hope Medical Center
- Registry record
- NCT05672342
Terminated
A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma
Reason given in the registry “The Sponsor terminated the study because development of cibisatamab has been discontinued.”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Aug 2024.
- Ended
- Mar 2024
- Phase
- Phase 1
- Run by
- Hoffmann-La Roche
- Registry record
- NCT03866239
Terminated
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
Reason given in the registry “Sponsor decision (not related to safety, efficacy or quality).”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Jul 2024.
- Ended
- Mar 2024
- Phase
- Phase 1
- Run by
- Hoffmann-La Roche
- Registry record
- NCT05769959
Withdrawn
Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer
Reason given in the registry “Due to slow patient recruiting. No patients were enrolled 12 months after study initiation.”
Quoted unchanged from ClinicalTrials.gov; record updated 9 Jul 2024.
- Ended
- Jul 2025
- Phase
- Phase 2
- Run by
- Sun Yat-sen University
- Registry record
- NCT05690035
Withdrawn
GI Organ Tracking Via Balloon Applicators
Reason given in the registry “Low accrual”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Jun 2024.
- Ended
- May 2025
- Run by
- Washington University School of Medicine
- Registry record
- NCT05471401
Terminated
Electroporation and Immunotherapy in Metastatic Colorectal Cancer
Reason given in the registry “The study was terminated on the basis on an evaluation of the efficacy and safety of the 4 included and treated patients.”
Quoted unchanged from ClinicalTrials.gov; record updated 3 Jun 2024.
- Ended
- May 2024
- Phase
- Phase 2
- Run by
- Ismail Gögenur
- Registry record
- NCT05609656
Terminated
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
Reason given in the registry “Not related to safety concerns or lack of efficacy”
Quoted unchanged from ClinicalTrials.gov; record updated 21 May 2024.
- Ended
- Apr 2024
- Phase
- Phase 1
- Run by
- ABM Therapeutics Corporation
- Registry record
- NCT04190628
Terminated
RITUAL Ultivision AI CADe Randomized Controlled Trial
Reason given in the registry “Business decision to discontinue the study. Discontinuation is not related to any patient safety or performance issues.”
Quoted unchanged from ClinicalTrials.gov; record updated 13 May 2024.
- Ended
- Feb 2024
- Run by
- Satisfai Health, Inc.
- Registry record
- NCT05732233
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.